Rahul Sharma (Editor)

Antibe Therapeutics

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Industry
  
Pharmaceuticals

Headquarters
  
Toronto, Canada

Website
  
www.antibethera.com

Antibe Therapeutics wwwantibetheracomwordpressimglogogif

Traded as
  
TSX-V: ATE OTCQX: ATBPF

Key people
  
Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Science Officer

Stock price
  
ATE (CVE) CA$ 0.26 +0.03 (+13.04%)24 Feb, 4:00 PM GMT-5 - Disclaimer

Type of business
  
Publicly traded corporation

Profiles

Facebook

Antibe therapeutics tsxv ate new listing


Antibe Therapeutics is a Toronto-based pharmaceutical company that develops inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. In 2015, Antibe acquired Citagenix, a developer and distributor involved in regenerative medicine.

Contents

Products

The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body. Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation. Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). ATB-346 is being developed to address osteoarthritis, although Antibe intends to broaden its application to rheumatoid arthritis and other diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the gastrointestinal tract.

In May 2014, the company announced that it had completed pre-clinical studies on ATB-346. In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials. In mid-January 2015, the company announced that clinical trials for its first drug were being suspended due to safety concerns; clinical trials were restarted in March 2015.

Antibe's products have not yet been approved by the US Food and Drug Administration.

People

Antibe's science advisory board:

  • Andre G. Buret, Professor, University of Calgary, Canada
  • Giuseppe Cirino, PhD, Professor, University of Naples, Italy
  • Gilberto de Nucci, MD, PhD, Professor, University of Sao Paulo, Brazil
  • Peter B. Ernst, DVM, PhD, Professor, UCSD, San Diego, USA
  • Derek Gilroy, PhD, Professor, University College, London, UK
  • Richard H. Hunt, MD, Emeritus Professor, McMaster University, Canada
  • Louis Ignarro, PhD Professor, UCLA, Los Angeles, USA - 1998 Nobel Prize Laureate in Medicine
  • Jane A. Mitchell, PhD, Professor, Imperial College, London, UK
  • Mauro Perretti, PhD, Professor, William Harvey Research Institute, London, UK
  • Daniel K. Podolsky, MD, President, University of Texas Southwestern Medical Center, USA
  • William Sessa, PhD, Professor, Yale University, USA
  • Philip M. Sherman, MD, Professor, University of Toronto, Canada

    • Antibe’s board of directors:

  • Chair - Walt Macnee, Vice Chair, MasterCard International
  • Roderick Flower, Professor, Barts and The London School of Medicine and Dentistry
  • Dan Legault, CEO, Antibe Therapeutics
  • Samira Sakhia, CFO, Paladin Labs
  • John L. Wallace, Chief Science Officer, Antibe Therapeutics

    • References

    Antibe Therapeutics Wikipedia
    (Text) CC BY-SA